← Back to Search

Dietary Supplement

XS Muscle Multiplier for Sarcopenia

N/A
Waitlist Available
Led By David D Church, Ph.D.
Research Sponsored by University of Arkansas
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Ages 18 - 30 and 70-89 yrs
For the sarcopenic group, a SARC-F score of ≥ 4 at the screening visit
Timeline
Screening 3 weeks
Treatment Varies
Follow Up a 5-hour period.
Awards & highlights

Study Summary

This trial will test if a new way of measuring muscle health is accurate. The results could help doctors learn about muscle health before patients experience a loss of function.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~a 5-hour period.
This trial's timeline: 3 weeks for screening, Varies for treatment, and a 5-hour period. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Maximum plasma leucine concentration.

Trial Design

1Treatment groups
Experimental Treatment
Group I: 10g of nutritional productExperimental Treatment1 Intervention
All subjects will ingest 10g of a commercially available nutritional supplement one time during a study visit.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
XS Muscle Multiplier
2022
N/A
~30

Find a Location

Who is running the clinical trial?

University of ArkansasLead Sponsor
485 Previous Clinical Trials
149,843 Total Patients Enrolled
8 Trials studying Sarcopenia
188 Patients Enrolled for Sarcopenia
David D Church, Ph.D.Principal InvestigatorUniversity of Arkansas

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~10 spots leftby Mar 2025